Currently Viewing:
Newsroom
Currently Reading
The Allen Institute for Immunology Plans Long-term Goal of Mapping the Immune System
December 15, 2018 – David Bai, PharmD
Osteoporosis Working Group Creates Recommendations for Economic Evaluations
December 15, 2018 – Allison Inserro
Federal Judge Strikes Down Affordable Care Act
December 15, 2018 – Allison Inserro and Mary Caffrey
Osteoporosis Screening Strategies Don't Identify Younger Women at Risk
December 14, 2018 – Allison Inserro
Study Determines Why Patients With HIV Have Higher Rates of Cancer
December 14, 2018 – Alison Rodriguez
Sofosbuvir-Based Therapy Safe in Patients With HCV and Certain Cancers
December 14, 2018 – Samantha DiGrande
Gender Differences Found in COPD Hospitalizations and In-Hospital Deaths
December 14, 2018 – Alison Rodriguez
Nontuberculous Mycobacterial Lung Disease Doubled the Risk of Death in a Managed Care Population
December 14, 2018 – Jackie Syrop
What We're Reading: Court Trims Birth Control Rule; Guns as Public Health Issue; California Lenient Toward Doctors
December 14, 2018 – AJMC Staff

AP: For Each Drug Price Cut, There Were 96 Price Hikes This Year So Far

Allison Inserro
Over the first 7 months of 2018, there were 96 price hikes for every price cut, an Associated Press (AP) analysis reported, although there were fewer and smaller price hikes than in years past.
Over the first 7 months of 2018, there were 96 price hikes for every price cut, an Associated Press (AP) analysis reported, although there were fewer and smaller price hikes than in years past.

The AP analyzed 26,176 list price changes for brand-name prescription drugs from January 1 through July 31 in the years 2015 through 2018, using data supplied by health information analytics firm Elsevier. The AP focused its analysis on the first 7 months of each year because of the seasonality of price changes and to make meaningful year-to-year comparisons. The data included more than 97% of price changes during those periods and, for many drugs, several dosages and drug forms.

Peter Bach, MD, who heads the Center for Health Policy and Outcomes at Memorial Sloan Kettering Cancer Center in New York, said that the AP’s analysis shows there’s been no big move to decrease prices. “We have a broken pricing system,” he said.

Last month, the Senate moved forward with a drug pricing transparency amendment to a spending bill in an effort to make good on at least 1 part of President Donald Trump’s plan to bring drug prices down. The bill will provide HHS with $1 million in funds to issue regulations on direct-to-consumer advertising. The regulations will require drug makers to include the prices of their products in direct-to-consumer advertisements.

However, there is no single price of a drug in the United States. For example, a drug’s wholesale acquisition cost, which is defined as the list price posted by manufacturers to customers, may not be the same as the average manufacturer price, which is defined as the average of prices that are actually paid by wholesalers and retailers who buy products from manufacturers directly.

Furthermore, the average sales price—which is the average amount of money realized by manufacturers after all rebates to pharmacy benefit managers, discounts, and price concessions have been made—may also represent a different sum. None of those measurements of drug price is likely to be the price paid by a typical patient whose out-of-pocket costs will vary by the type of insurance coverage they have. And of course, patients in high-deductible health plans, or who are uninsured, may have to pay the entire amount or even go without medicine.  Last week, the latest Kaiser Family Foundation health tracking poll found that Americans continue to be alarmed by health costs, including drug prices, ahead of the midterm elections. More than 4 in 10 adults worry about affording prescription drug costs, the poll found. When asked about the effectiveness of the Trump administration’s plan to lower prescription drug prices, a majority (55%) said the president’s strategy of publicly calling on drug companies to lower their costs will not be too effective or at all effective.

President Trump made reducing drug prices a key promise during his election campaign, repeatedly accusing drugmakers of “getting away with murder.” At the end of May, he promised that drug companies would be announcing “massive” voluntary drug price cuts within 2 weeks.

But HHS Secretary Alex Azar said in a recent AP interview that it will be a while before drug prices fall, citing the complexity of the pharmaceutical market and its incentives for drugmakers to boost prices so they and pharmacy benefit managers make bigger profits.

Elsevier drug pricing expert Kay Morgan told the AP that the data indicate companies are being more cautious about price increases, but Trump’s criticisms are just 1 factor. She cited frequent media coverage, patients and their advocacy groups pressuring members of Congress to fight high drug prices, and Congress holding hearings on huge price increases.

“The rate of increases has slowed down, but prices haven’t decreased,” Stephen Schondelmeyer, PharmD, PhD, a University of Minnesota professor of pharmaceutical economics who runs its research program on drug prices and public policy, told the AP. He said such temporary pricing restraint occurs periodically around elections and other times when the issue is hot, but then companies go back to raising drug prices.

Edward Jones drug analyst Ashtyn Evans said that “companies are self-policing more.” She noted many firms are raising prices once a year, at about 10%, instead of issuing 2 or 3 smaller hikes each year.

Among the AP’s findings:
  • There were fewer price increases this year from January through July than in comparable prior-year periods, but companies still hiked prices far more often than they cut them. This year through the end of July, there were 4412 brand-name drug price increases and 46 price cuts, a ratio of 96 to 1.
  • In June and July, right after Trump’s price cut prediction, there were 395 price increases and 24 decreases. The 2 dozen cuts were up from the 15 decreases in those same 2 months last year, but increases still outpaced decreases by a ratio of 16.5 to 1.
  • The median price increase was 5.2% in June and July of 2018, down from 8% in that period in 2017.
  • The median price cut this June and July was 11%, much smaller than in comparable periods in prior years.


Related Articles

What Is and Is Not in Trump's Drug Pricing Plan: An Interview With Dr Michael Chernew
Dr. Michael Chernew Discusses Trump Drug Pricing Plan in Managed Care Cast, an AJMC® Podcast
Novartis Will Freeze Drug Prices Through End of 2018, CEO Says
Drug Prices Not Consistently Aligned With Value, Analysis Finds
5 Actions Taken Since the Release of Trump's Drug Pricing Blueprint
 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!